Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure

Sola, Srikanth; Mir, Muhammad Q.S.; Lerakis, Stamatios; Tandon, Neeraj; Khan, Bobby V.

doi:10.1016/j.jacc.2005.06.088

Cited by 293 publications

(222 citation statements)

References 32 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…Our finding that atorvastatin can improve both systolic and diastolic dysfunction is in good agreement with several recent clinical observations (2)(3)(4)(5). Considering that a relatively low proportion of patients with non-ischemic heart failure receive statin therapy and a relatively high proportion of CHF patients have diastolic dysfunction, use of statins to treat CHF should be increased.…”

Section: Fig 5 Atorvastatin Inhibited the Egfr-erk Signaling Pathwasupporting

confidence: 91%

“…Therefore, investigation of novel treatments to improve the prognosis of CHF is an area of intense activity. Recent clinical studies performed by us as well as others have shown that hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) improve cardiac remodeling and survival in patients with either ischemic or non-ischemic CHF (2)(3)(4)(5), suggesting that statin therapy may be a potential new approach for CHF. Randomized double-blind placebo-controlled trials that are still ongoing (6,7) may eventually provide firm evidence about this issue.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Fig 5 Atorvastatin Inhibited the Egfr-erk Signaling Pathwasupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Previous studies [34][35] have demonstrated the pivotal role of inflammation in adverse LV function. Patients with heart failure often have elevated levels of pro-inflammatory cytokines and chemokines.…”

Section: Wwwchinapharcom Zhang Y Et Almentioning

confidence: 98%

Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization

Zhang

Guo

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim:We have shown that a combination of ligustrazine and berberine produces more effective inhibition on platelet activation and inflammatory reactions in rat acute myocardial infarction compared with either agent alone. In this study we evaluated the beneficial effects of a combination of ligustrazine and berberine in a rat model of coronary microembolization (CME). Methods: SD rats were treated with ligustrazine, berberine, ligustrazine+berberine, or clopidogrel for 2 weeks. When the treatment completed, CME was induced by injection of sodium laurate into the left ventricular, while obstructing the ascending aorta. All rats were intubated for hemodynamic measurements. Blood samples were collected for biochemical analyses, flow cytometry, and ELISAs. Heart tissues were isolated for histopathology and subsequent protein analyses. Results: Pretreatment with the combination of ligustrazine (27 mg·kg -1 ·d -1 ) and berberine (90 mg·kg -1 ·d -1 ) significantly improved cardiac function, and decreased myocardial necrosis, inflammatory cell infiltration, microthrombosis and serum CK-MB levels in CME rats. In addition, this combination significantly decreased plasma ET-1 levels and von Willebrand factor, inhibited ADP-induced platelet activation, and reduced TNFα, IL-1β, ICAM-1 and RANTES levels in serum and heart tissues. The protective effects of this combination were more prominent than those of ligustrazine or berberine alone, but comparable to those of a positive control clopidogrel (6.75 mg·kg -1 ·d -1 ). Conclusion: The combination of ligustrazine and berberine significantly improved cardiac function in rat CME model via a mechanism involving antiplatelet and anti-inflammatory effects.

show abstract

“…Sola et al [175] found that administration of atorvastatin improved left ventricular ejection fraction and attenuated adverse left ventricular remodeling in patients with nonischemic heart failure. Atorvastatin also dampened the inflammatory process in patients with heart failure [176] .…”

Section: Endoplasmic Reticulum Stress Is Involved In the Development mentioning

confidence: 99%

Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases

2016

View full text Add to dashboard Cite

Endoplasmic reticulum is a principal organelle responsible for folding, post-translational modifications and transport of secretory, luminal and membrane proteins, thus palys an important rale in maintaining cellular homeostasis. Endoplasmic reticulum stress (ERS) is a condition that is accelerated by accumulation of unfolded/misfolded proteins after endoplasmic reticulum environment disturbance, triggered by a variety of physiological and pathological factors, such as nutrient deprivation, altered glycosylation, calcium depletion, oxidative stress, DNA damage and energy disturbance, etc. ERS may initiate the unfolded protein response (UPR) to restore cellular homeostasis or lead to apoptosis. Numerous studies have clarified the link between ERS and cardiovascular diseases. This review focuses on ERS-associated molecular mechanisms that participate in physiological and pathophysiological processes of heart and blood vessels. In addition, a number of drugs that regulate ERS was introduced, which may be used to treat cardiovascular diseases. This review may open new avenues for studying the pathogenesis of cardiovascular diseases and discovering novel drugs targeting ERS.

show abstract

Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure

Abstract: The use of atorvastatin in patients with nonischemic HF improves LVEF and attenuates adverse LV remodeling. The effects on soluble levels of several inflammatory markers with atorvastatin suggest, in part, mechanisms by which statins might exert their beneficial effects in nonischemic HF.

Cited by 293 publications

References 32 publications

Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation

Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation

Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization

Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases

Contact Info

Product

Resources

About